Statistics

Total Visits

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial109

File Visits

Downloads
VERSION EDITOR.pdf22

Select a period of time:

Number of views in the range

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial51

Number of downloads in the range

Downloads
VERSION EDITOR.pdf10

Views

Views
July 202517
August 20253
September 20255
October 20251
November 20255
December 20257
January 202613
Download CSV file
 untranslated
 untranslated

Number of downloads in the period of time

  • Downloads
  • July 2025
    0
  • August 2025
    1
  • September 2025
    2
  • October 2025
    0
  • November 2025
    0
  • December 2025
    4
  • January 2026
    3
  • Download CSV file
 untranslated
 untranslated

Top country views

Views
United States23
Brazil7
United Kingdom4
Mexico3
Canada2
Ecuador2
Uruguay2
Argentina2
Barbados1
Bangladesh1
 

Top countries by downloads

Downloads
United States10
 

Top cities views

Views
San Jose7
Ashburn7
Montevideo2
Addis Ababa1
Barbacena1
Chino Valley1
Cochabamba1
Coronel Brandsen1
Guadalajara1
Guanajuato City1
 

Top cities by downloads

Downloads
Ashburn1